|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
1R44CA124032-01A1
|
$101,130
|
$50,565
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Clinical study of AdV-tk radiogenetherapy for malignant*
|
4R44CA107745-03
|
$788,188
|
$394,094
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Clinical study of GMCI in Pancreatic Cancer
|
5R43CA119847-02
|
$376,666
|
$94,167
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Immuno/Immunogene Therapies for Thoracic Malignancies
|
5P01CA066726-11
|
$1,181,405
|
$590,703
|
Albelda, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Infectivity Enhanced Virotherapy For Ovarian Cancer
|
1R21CA128222-01
|
$275,500
|
$275,500
|
Alvarez, Ronald
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Enhanced Adenoviral Vectors for Ovarian Cancer
|
5R01CA090547-04
|
$205,761
|
$102,881
|
Alvarez, Ronald
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Southeast Cancer Control Consortium, Inc
|
3U10CA045808-21S1
|
$170,000
|
$1,700
|
ATKINS, JAMES
|
SOUTHEAST CANCER CONTROL CONSORTIUM
|
|
Southeast Cancer Control Consortium, Inc
|
5U10CA045808-21
|
$1,860,642
|
$18,606
|
ATKINS, JAMES
|
SOUTHEAST CANCER CONTROL CONSORTIUM
|
|
WUMC-Cancer and Leukemia Group B
|
5U10CA077440-10
|
$334,381
|
$23,407
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
University of Texas MD Anderson SPORE in Ovarian Cancer
|
5P50CA083639-08
|
$2,249,522
|
$449,904
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Cancer and Leukemia Group B - The Ohio State University
|
5U10CA077658-10
|
$434,962
|
$30,447
|
BLOOMFIELD, CLARA
|
OHIO STATE UNIVERSITY
|
|
Cancer and Leukemia Group B-Leukemia Correlative Science
|
5U10CA101140-05
|
$994,868
|
$69,641
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
THERAPY OF CML
|
5P01CA049639-19
|
$3,552,240
|
$355,224
|
CHAMPLIN, RICHARD
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCY
|
1R21CA116127-01A1
|
$202,499
|
$202,499
|
COOPER, LAURENCE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Cancer and Leukemia Group B
|
5U10CA047577-20
|
$160,142
|
$11,210
|
CRAWFORD, JEFFREY
|
DUKE UNIVERSITY
|
|
Monitoring of advanced virotherapy for ovarian cancer
|
1R01CA121187-01A2
|
$272,422
|
$89,899
|
Curiel, David
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
SPORE in Genitourinary Cancer
|
5P50CA091846-07
|
$2,549,962
|
$509,992
|
DINNEY, COLIN
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
A Phase I Trial of CCL-21 Gene Modified DC in NSCLC
|
5R21CA105705-02
|
$331,634
|
$331,634
|
Dubinett, Steven
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
PET IMAGING OF MART TCR-ENGINEERED CD8 T CELL IMMUNOTHERAPY IN MAN
|
1R01CA129816-01
|
$279,344
|
$279,344
|
ECONOMOU, JAMES
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Dendritic Cell-Based Genetic Immunotherapy for Melanoma
|
3R01CA079976-08S2
|
$124,483
|
$93,362
|
ECONOMOU, JAMES
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Nevada Cancer Research Foundation-Community Clinical Oncology Program
|
2U10CA035421-24
|
$650,000
|
$6,500
|
ELLERTON, JOHN
|
SOUTHERN NEVADA CANCER RESEARCH FDN
|
|
Bay Area Tumor Institute CCOP
|
2U10CA045461-18
|
$480,000
|
$4,800
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
Quality Assurance Review Center
|
2U10CA029511-28
|
$1,871,106
|
$18,711
|
FITZGERALD, THOMAS
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
Cancer and Leukemia Group B
|
5U10CA041287-22
|
$266,860
|
$18,680
|
FLEMING, GINI
|
UNIVERSITY OF CHICAGO
|
|
Hematopoietic Cell Transplantation for Hematologic Malignancies
|
3P01CA030206-25S1
|
$89,324
|
$17,865
|
FORMAN, STEPHEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Hematopoietic Cell Transplantation for Hematologic Malignancies
|
5P01CA030206-25
|
$2,776,839
|
$555,368
|
FORMAN, STEPHEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Molecular Gene and Radiation Therapies for Cancer
|
5P01CA097012-04
|
$1,347,203
|
$336,801
|
FREYTAG, SVEND
|
HENRY FORD HEALTH SYSTEM
|
|
Kansas City Clinical Oncology Program CCOP
|
5U10CA035176-24
|
$672,441
|
$6,724
|
Gaur, Rakesh
|
KANSAS CITY CLINICAL ONCOLOGY PROGRAM
|
|
Cancer and Leukemia Group B Statistical Center
|
5U10CA033601-28
|
$5,064,881
|
$354,542
|
GEORGE, STEPHEN
|
DUKE UNIVERSITY
|
|
Developing Nucleic Acid Therapeutics
|
5R01CA101859-05
|
$267,510
|
$133,755
|
Gewirtz, Alan
|
UNIVERSITY OF PENNSYLVANIA
|
|
Greenville SC CCOP
|
2U10CA067663-12
|
$740,000
|
$7,400
|
GIGUERE, JEFFREY
|
ONCOLOGY & HEMATOLOGY ASSOCIATES OF SC
|
|
Greenville SC CCOP
|
3U10CA067663-12S1
|
$100,000
|
$1,000
|
Giguere, Jeffrey
|
ONCOLOGY & HEMATOLOGY ASSOCIATES OF SC
|
|
Molecular Therapeutics for Anaplastic Gliomas
|
3P50CA097247-05S2
|
$1,073,000
|
$429,200
|
GILLESPIE, G.
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Molecular Therapeutics for Anaplastic Gliomas
|
3P50CA097247-05S3
|
$129,320
|
$51,728
|
GILLESPIE, G.
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Phase I Trials of Anti-Cancer Agents
|
5U01CA076576-10
|
$701,378
|
$28,055
|
GREVER, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
Community Clinical Oncology Program
|
5U10CA035199-24
|
$413,073
|
$4,131
|
Grinblatt, David
|
EVANSTON NORTHWESTERN HEALTHCARE
|
|
Delaware/Christiana Care CCOP
|
2U10CA045418-21
|
$835,003
|
$8,350
|
GRUBBS, STEPHEN
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Delaware/Christiana Care CCOP
|
3U10CA045418-21S1
|
$119,011
|
$1,190
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
The UCLA Center for In Vivo Imaging in Cancer Biology
|
5P50CA086306-08
|
$1,891,032
|
$472,758
|
HERSCHMAN, HARVEY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Gene Therapy for Brain Tumors
|
3P01CA069246-11S1
|
$40,392
|
$14,137
|
HOCHBERG, FRED
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Gene Therapy for Brain Tumors
|
5P01CA069246-11
|
$1,357,853
|
$475,249
|
HOCHBERG, FRED
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
CANCER AND LEUKEMIA GROUP B
|
5U10CA077651-10
|
$264,314
|
$18,502
|
Hudis, Clifford
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Cancer and Leukemia Group B
|
5U10CA003927-50
|
$247,998
|
$17,360
|
HURD, DAVID
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
Radiologial Physics Center
|
5U10CA010953-39
|
$2,431,121
|
$24,311
|
IBBOTT, GEOFFREY
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
SPORE in Prostate Cancer
|
3P50CA058204-13S1
|
$1,124,001
|
$112,400
|
ITTMANN, MICHAEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Chronic Lymphocytic Leukemia Research Consortium
|
5P01CA081534-08
|
$3,827,483
|
$765,497
|
KIPPS, THOMAS
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Syracuse Hematology-Oncology CCOP
|
5U10CA045389-21
|
$536,473
|
$5,365
|
KIRSHNER, JEFFREY
|
HEMATOLOGY-ONCOLOGY ASSOCIATES/CTL NY
|
|
Transfer of the CD40 ligand gene to esophageal carcinoma
|
5R01CA101982-05
|
$357,594
|
$357,594
|
KORST, ROBERT
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
|
Illinois Oncology Research Association CCOP
|
3U10CA035113-24S1
|
$120,000
|
$1,200
|
KUGLER, JOHN
|
ONCOLOGY-HEMATOLOGY ASSOC-CENTRAL ILL
|
|
Illinois Oncology Research Association CCOP
|
5U10CA035113-24
|
$578,969
|
$5,790
|
KUGLER, JOHN
|
ONCOLOGY-HEMATOLOGY ASSOC-CENTRAL ILL
|
Total relevant funding to Gene Therapy Clinical Trials for this search: $16,341,118
|